CYTK vs EWTX
CYTK: A clinical-stage biopharmaceutical firm pioneering muscle-directed therapies for cardiovascular and neuromuscular diseases. EWTX: A clinical-stage biopharmaceutical company developing oral, precision small molecule medicines for the treatment of serious cardiovascular diseases.
Side-by-side fundamentals
| Metric | CYTK | EWTX | Edge |
|---|---|---|---|
| Price as of 2026-10-21 close | $62.86 | $39.65 | |
| Market cap | $8.7B | $4.3B | |
| Net margin FY2025, SEC XBRL | -891.6% | n/a | |
| Operating margin FY2025, SEC XBRL | -695.4% | n/a | |
| ROE FY2025, SEC XBRL | n/a | -32.1% | |
| ROA FY2025, SEC XBRL | -55.1% | -30.4% | EWTX higher |
| Revenue growth (YoY) FY2025, SEC XBRL | +376.6% | n/a | |
| Revenue CAGR (3y) SEC XBRL | -2.4% | n/a | |
| Dividend streak (yrs) SEC XBRL | 0 | 0 | Tie |
| Beta as of 2026-09-03 | 0.71 | 1.16 | |
| 1-year return as of 2026-10-21 close | +8.8% | +155.6% | EWTX higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.